In the “FDA-approved different tumor type” category, brain tumors were the most common cancer category (n = 16, 25.0%) with PD-1/PD-L1 inhibitors (n = 6, 38%), CDK4/6 (n = 3, 19%), and EGFR (n = 3, 19%) inhibitors the most common treatments. This evidence concerns the gene EGFR and neoplasm.